This has nothing to do with RD--ARDS is an acute inflammatory lung disease. Ten seconds of Googling prior to emptying both barrels might have been a good idea.
You should also try to discriminate upfront payments from milestones. $330 million in Biobuck potential milestones doesn't say anything about Big Pharma's 'pockets'--watch the upfronts.
Postscript: I see that Athero already provided a more substantive clarification,
Market Data 
Markets 
AI
